Q2 2025 Ambu A/S Earnings Call Transcript
Key Points
- Ambu AS (AMBFF) reported a solid organic revenue growth of 15.4% for the first half of the fiscal year, aligning with their adjusted guidance.
- The company successfully launched the Ambu SureSight Connect in the US and UK, marking a strong start for this new product.
- Ambu AS (AMBFF) maintained a strong EBIT margin of 15.2% in the first half of the year, confirming their upgraded guidance.
- The company achieved a positive free cash flow of DKK 80 million, indicating strong financial health.
- Ambu AS (AMBFF) continues to invest in growth and operational excellence, optimizing their organization for future growth targets.
- The company faces potential challenges from new competition, particularly from Chinese players in the US market, which could impact sales cycles.
- There is a risk of tariffs impacting financial performance, especially for products manufactured in Malaysia and China.
- Ambu AS (AMBFF) experienced a slowdown in growth for the ENT, urology, and GI segments, with a need to address competitive pressures.
- The company's effective tax rate was unusually low due to a one-off tax case resolution, which may not be sustainable.
- Higher inventory levels have impacted cash flow, and the company needs to manage networking capital effectively to meet cash flow guidance.
/- -
Hello everyone and welcome to today's conference call with Ambu where we are going to announce and talk about our results from Q2 and the first half of our fiscal year 2024-2025. My name is Britt Meelby Jensen. I'm the CEO of Ambu, and with me today I have the pleasure of introducing Henrik Skak Bender, our CFO.
We will start with the presentation of the results, and then we will open up the floor for questions. But let me start with the highlights and the key messages that we have. If we look at the first half of our fiscal year, we delivered a solid organic revenue growth, bringing our first half of the year up to a total organic revenue growth of 15.4%. This is in line with our own expectations and in line with our adjusted guidance from January.
Also, we had a strong start on our very important launch Ambu SureSight Connect, and we continue good momentum on our urology launches when it comes to our aScope 5 Cysto HD and our aScope. I will come back later
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
